Rapid Micro Biosystems(RPID) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total fourth quarter revenue reached $11.3 million, representing a 37% year-over-year growth and a quarterly record, exceeding previous guidance [9][19] - Product revenue increased by 78% in Q4, driven by strong system placements, while consumable revenue grew by 11% [11][19] - Recurring revenue increased by 15% for the full year, accounting for 53% of total revenue, indicating strong utilization of installed systems [11] Business Line Data and Key Metrics Changes - The company placed 16 Growth Direct systems in Q4, a record number, bringing the total to 190 systems globally, with 155 fully validated [9][19] - Service revenue was $2 million in Q4, consistent with guidance, but lower than $3 million in Q4 2024 due to timing of validations [20] Market Data and Key Metrics Changes - The partnership with MilliporeSigma is expected to contribute significantly to system placements in 2026, with ongoing training and demo labs established across Europe and Asia [12][15] - The company is seeing strong demand from both principal manufacturers and CDMOs, with significant orders from Amgen and Samsung Biologics [10][15] Company Strategy and Development Direction - The company aims to accelerate system placements, expand gross margins, innovate new products, and manage cash prudently [13][30] - A new cloud-native software platform is expected to be released in the second half of 2026, enhancing customer experience and providing AI-driven analytics [17][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a full-year 2026 revenue guidance of $37 million to $41 million, with expectations for gross margin expansion to approximately 20% [18][29] - The company anticipates strong tailwinds from increased automation adoption and a focus on data integrity in the pharmaceutical industry [16] Other Important Information - Fourth quarter gross margin was impacted by inventory-related charges, but significant progress was made in reducing product costs and improving manufacturing efficiencies [11][21] - The company ended the year with $39 million in cash and investments, aligning with guidance [24] Q&A Session Summary Question: What is being done to reduce the gap between placed and validated systems? - Management indicated that timing variations affect the validation process and expects to see the gap decrease as they work with customers [32][34] Question: What percentage of placed systems are within CDMOs, and how is that space evolving? - Management noted a strong value proposition for CDMOs and highlighted significant orders from both CDMOs and principal manufacturers [35][37] Question: What are the key drivers for achieving the 20% gross margin target for 2026? - Key drivers include locked-in product cost reductions and expected increases in service revenues as validations progress [41][43] Question: How will the next-gen cloud-native software platform be integrated into devices? - The platform will be a complete rewrite of the application software, providing easier integration and potential future revenue from cloud services [67][68] Question: What moves are being made to drive consumable cost reductions? - The company is working with various vendors to achieve significant cost reductions, which will benefit gross margins in 2026 [72][74]